<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519556</url>
  </required_header>
  <id_info>
    <org_study_id>ProbioticsAD2015</org_study_id>
    <nct_id>NCT02519556</nct_id>
  </id_info>
  <brief_title>Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children</brief_title>
  <official_title>Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children up to 6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Casa Espirita Terra de Ismael</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Casa Espirita Terra de Ismael</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis (AD) is an immune disorder, characterized by chronic skin inflammation or
      relapsing, whose prevalence is increasing worldwide. Its exact etiology remains unknown. The
      hypothesis that an appropriate early stimulation of the intestinal flora contributes to the
      establishment of the immune system balance has led to the use of probiotics in the prevention
      and treatment of AD in several clinical and experimental studies.

      Therefore, the objectives of this study will evaluate the clinical efficacy of the mixture of
      probiotics (Lactobacillus and Bifidobacterium) in children with AD through the SCORAD
      (scoring atopic dermatitis) and to evaluate the effects of this medication in the following
      laboratory parameters: skin prick test, total serum immunoglobulin E (IgE), inflammation
      composite (interferon gamma [ɣ - IFN], interleukins [IL1-β, IL-4, IL-6, IL-8] and tumor
      necrosis factor alpha) and immune tolerance composite (IL-10, IL-17 and transforming growth
      factor beta [TGF - β]).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCORAD</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline in SCORAD every 3 months for 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin prick test (immediate awareness)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation composite</measure>
    <time_frame>1 year</time_frame>
    <description>ɣ - IFN, IL-1β, IL -4 , IL -6, IL-8 and tumor necrosis factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance composite</measure>
    <time_frame>1 year</time_frame>
    <description>IL-10, TGF - β and IL -17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum IgE</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Probiatop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Maltodextrin in sachet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiatop</intervention_name>
    <description>Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.</description>
    <arm_group_label>Probiatop</arm_group_label>
    <other_name>Probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Atopic Dermatitis

          -  Children over 6 months.

          -  Teens lower than 19 years

        Exclusion Criteria:

          -  Diagnostic presence or clinical signs suggesting acute or chronic skin diseases, as
             well as pertinent to the study, which may affect the outcome of the research.

          -  Being in use of drugs that can affect systemically in the course of the disease, such
             as systemic corticosteroids and immunosuppressants, for at least 30 days.

          -  Allergy or severe adverse reactions attributable to the administration of the
             probiotic.

          -  Non adherence to treatment (ie not present regular use, as prescribed) for at least
             one continuous month.

          -  Lack of attendance by more than 50% of ratings (clinical and/or laboratory) to be held
             during the search.

          -  Patient's request (or responsible's request)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCFMRP-USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Persio Roxo-Junior, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>HCFMRP-USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanessa Carregaro, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>USP-RP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorgete Maria e Silva, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>HCFMRP-USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciana Roberti</last_name>
    <role>Study Chair</role>
    <affiliation>FMRP-USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laís Sacramento, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>USP-RP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas FMRP-USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Casa Espirita Terra de Ismael</investigator_affiliation>
    <investigator_full_name>Fabio Carmona</investigator_full_name>
    <investigator_title>University of Sao Paulo</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Awareness</keyword>
  <keyword>Immune tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

